Oregon Health and Science University

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Rehabilitation of the Upper Extremity With Enhanced Proprioceptive Feedback Following Incomplete Spinal Cord Injury

Not Applicable

Completed

Conditions: Spinal Cord Injury
Paresis
Tetraplegia
Plegia

Interventions: Device: AMES treatment

First Posted Date: 2009-01-30

Last Posted Date: 2019-05-01

Lead Sponsor: Oregon Health and Science University

Target Recruit Count: 13

Registration Number: NCT00833105

Locations: 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸
Shepherd Center, Atlanta, Georgia, United States

Clinical Trial Examining Effects of Monosodium Glutamate (MSG) on Irritable Bowel Syndrome (IBS) and Fibromyalgia (FM)

Not Applicable

Completed

Conditions: Irritable Bowel Syndrome
Fibromyalgia

Interventions: Other: Glutamate additive-free diet
Other: Placebo diet

First Posted Date: 2009-01-26

Last Posted Date: 2013-12-24

Lead Sponsor: Oregon Health and Science University

Target Recruit Count: 60

Registration Number: NCT00829218

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Home-based Self-delivered Mirror Therapy for Phantom Limb Pain

Early Phase 1

Completed

Conditions: Phantom Limb Pain

Interventions: Behavioral: Mirror Therapy

First Posted Date: 2009-01-22

Last Posted Date: 2019-10-15

Lead Sponsor: Oregon Health and Science University

Target Recruit Count: 40

Registration Number: NCT00827294

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

A Translational Approach to Gitelman Syndrome

Not Applicable

Completed

Conditions: Gitelman Syndrome

Interventions: Drug: Hydrochlorothiazide

First Posted Date: 2009-01-14

Last Posted Date: 2019-04-05

Lead Sponsor: Oregon Health and Science University

Target Recruit Count: 8

Registration Number: NCT00822107

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

VANOS Cream and Skin Barrier Function

Phase 4

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Fluocinonide

First Posted Date: 2009-01-09

Last Posted Date: 2017-07-11

Lead Sponsor: Oregon Health and Science University

Target Recruit Count: 25

Registration Number: NCT00819507

Locations: 🇺🇸
Oregon Health & Science University Department of Dermatology, Portland, Oregon, United States

Pulp Capping With Two Different Agents

Not Applicable

Completed

Conditions: Dental Pulp Exposure

Interventions: Drug: Mineral Trioxide Aggregate
Drug: Calcium Hydroxide

First Posted Date: 2008-12-22

Last Posted Date: 2015-05-25

Lead Sponsor: Oregon Health and Science University

Target Recruit Count: 376

Registration Number: NCT00812877

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Cognitive Behavioral Therapy for Depression in Parkinson's Disease

Not Applicable

Terminated

Conditions: Parkinson's Disease
Depression

Interventions: Behavioral: Cognitive Behavioral Therapy

First Posted Date: 2008-12-18

Last Posted Date: 2014-10-24

Lead Sponsor: Oregon Health and Science University

Target Recruit Count: 12

Registration Number: NCT00810628

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: emollient (Cetaphil cream)

First Posted Date: 2008-12-10

Last Posted Date: 2017-07-11

Lead Sponsor: Oregon Health and Science University

Target Recruit Count: 22

Registration Number: NCT00806221

Locations: 🇺🇸
Oregon Health & Science University, Department of Dermatology, Portland, Oregon, United States

An in Vivo Comparison of the Debridement Efficiency of Needle Irrigation Versus Ultrasonic Irrigation

Not Applicable

Withdrawn

Conditions: Extirpation of the Tooth Pulp

Interventions: Device: Needle Irrigation
Device: Vista Ultrasonic Bleach Bypass System

First Posted Date: 2008-12-10

Last Posted Date: 2019-06-12

Lead Sponsor: Oregon Health and Science University

Registration Number: NCT00806273

Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration

Phase 2

Completed

Conditions: Age-Related Macular Degeneration

Interventions: Drug: combination ranibizumab + bromfenac
Drug: ranibizumab injection alone

First Posted Date: 2008-12-09

Last Posted Date: 2011-07-22

Lead Sponsor: Oregon Health and Science University

Target Recruit Count: 30

Registration Number: NCT00805233

Locations: 🇺🇸
Casey Eye Institute at Oregon Health & Science University, Portland, Oregon, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy